Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.
about
Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host diseaseEvaluation of different tests based on observations for external model evaluation of population analyses.Clinical pharmacology = disease progression + drug actionPhysiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibitionWeight-HbA1c-insulin-glucose model for describing disease progression of type 2 diabetesPharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus.Modeling NSCLC progression: recent advances and opportunities availableModeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats.Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.Controlled porosity solubility modulated osmotic pump tablets of gliclazide.Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms.Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.Mixture modeling for the detection of subpopulations in a pharmacokinetic/pharmacodynamic analysis.Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus.
P2860
Q28299731-52C2D00B-9EB0-44DE-BF61-E10C78EFBD87Q33869167-F4C3B82C-96AB-496A-AE58-8951745BB20BQ34953659-84265212-C084-44F2-B3E7-FA49FC0850ECQ35825657-A2AC8E62-DA72-413C-A1DC-18F941F12029Q36506476-D145D534-D2AF-4766-A345-380F30C9C361Q36693706-E7E54FA0-9191-43D3-9147-05BF965862DCQ36910615-21C744A9-CB49-42CA-9894-FCAF8BC608ABQ36952913-CD97752F-A559-4E7D-9B1E-FADD2348689BQ37149129-E5AA567A-B964-4502-80F3-633EAF2AD62CQ39959170-7A60EB0F-0254-4388-BE48-63F0E9A1C4F9Q40510093-77839475-4589-41CA-87D3-ED82D9C11E0CQ41110266-39D284BA-9C2E-4E00-ACF6-0DCCF2DCC704Q41556354-07E39298-E2F5-4B79-B118-B143392E0910Q41812080-423B9A17-603D-4A25-A8E0-19719C7A5C95Q42117272-306B1D84-73FD-465B-A825-553E62B879DCQ43059458-943011EE-09F7-487A-9398-0EE39C62B922Q46051003-69D5AAC7-76D0-4D95-8B68-D18322413D77Q46677274-0FBFD934-584B-40F6-8680-16DC648AF234
P2860
Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Population PKPD modelling of t ...... fied release (MR) formulation.
@ast
Population PKPD modelling of t ...... fied release (MR) formulation.
@en
type
label
Population PKPD modelling of t ...... fied release (MR) formulation.
@ast
Population PKPD modelling of t ...... fied release (MR) formulation.
@en
prefLabel
Population PKPD modelling of t ...... fied release (MR) formulation.
@ast
Population PKPD modelling of t ...... fied release (MR) formulation.
@en
P2093
P2860
P1476
Population PKPD modelling of t ...... ified release (MR) formulation
@en
P2093
C Laveille
M Francillard
Roeline Jochemsen
P2860
P304
P356
10.1046/J.1365-2125.2003.01751.X
P407
P50
P577
2003-02-01T00:00:00Z